文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

CRISPR/Cas9编辑α珠蛋白位点纠正β地中海贫血

Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
PubMed 文献 · Blood Adv · 2021-01-01

β地中海贫血由β珠蛋白基因突变引起,α珠蛋白过剩导致溶血和无效造血。本研究在人类造血干/祖细胞中利用CRISPR/Cas9同时敲除HBA2基因以模拟α地贫特质并整合β珠蛋白转基因,在细胞模型和患者HSPCs中纠正了α/β珠蛋白失衡,且编辑后HSPCs保持长期重建能力。

要点

  • CRISPR/Cas9同时敲除HBA2和整合β珠蛋白转基因可纠正α/β失衡
  • 编辑后的健康供者HSPCs在异种移植小鼠中保持长期重建和多能性
  • 使用Cas9切口酶可实现精确编辑且无插入缺失

核心结论

  • 在人类HSPCs中编辑α珠蛋白位点可改善β地贫的α/β珠蛋白失衡。

研究设计与样本

  • 临床前研究:在人红系祖细胞模型(HUDEP-2 β0)、健康供者及β地贫患者HSPCs中进行CRISPR/Cas9编辑。
  • 使用异种移植小鼠评估编辑后HSPCs的长期重建能力和多能性。

主要发现

  • 在HUDEP-2 β0细胞模型中优化CRISPR/Cas9策略并纠正病理表型。
  • 编辑的健康供者HSPCs在异种移植小鼠中保持长期重建能力和多能性。
  • 编辑的β地贫患者HSPCs来源红系母细胞中α/β珠蛋白失衡得到纠正。
  • 使用Cas9切口酶在HSPCs中实现精确编辑且无InDels。

临床怎么用

  • 该策略为β地贫提供新型治疗思路:编辑α珠蛋白位点而非直接修复HBB。
  • Cas9切口酶编辑可能作为更安全的临床转化选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-thalassemias (β-thal) are a group of blood disorders caused by mutations in the β-globin gene (HBB) cluster. β-globin associates with α-globin to form adult hemoglobin (HbA, α2β2), the main oxygen-carrier in erythrocytes. When β-globin chains are absent or limiting, free α-globins precipitate and damage cell membranes, causing hemolysis and ineffective erythropoiesis. Clinical data show that severity of β-thal correlates with the number of inherited α-globin genes (HBA1 and HBA2), with α-globin gene deletions having a beneficial effect for patients. Here, we describe a novel strategy to treat β-thal based on genome editing of the α-globin locus in human hematopoietic stem/progenitor cells (HSPCs). Using CRISPR/Cas9, we combined 2 therapeutic approaches: (1) α-globin downregulation, by deleting the HBA2 gene to recreate an α-thalassemia trait, and (2) β-globin expression, by targeted integration of a β-globin transgene downstream the HBA2 promoter. First, we optimized the CRISPR/Cas9 strategy and corrected the pathological phenotype in a cellular model of β-thalassemia (human erythroid progenitor cell [HUDEP-2] β0). Then, we edited healthy donor HSPCs and demonstrated that they maintained long-term repopulation capacity and multipotency in xenotransplanted mice. To assess the clinical potential of this approach, we next edited β-thal HSPCs and achieved correction of α/β globin imbalance in HSPC-derived erythroblasts. As a safer option for clinical translation, we performed editing in HSPCs using Cas9 nickase showing precise editing with no InDels. Overall, we described an innovative CRISPR/Cas9 approach to improve α/β globin imbalance in thalassemic HSPCs, paving the way for novel therapeutic strategies for β-thal.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pavani G, Fabiano A, Laurent M, et al. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells. Blood Adv. 2021. PMID: 33635334. doi:10.1182/bloodadvances.2020001996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。